Irisin Expression and Gene Polymorphism With Peripartum Cardiomyopathy.
Overview
this is an observertional study aimed at Study the association between the level of irisin expression and (Fibronectin Type III Domain Containing 5 (FDNC5) gene polymorphism in female patients with peripartum cardiomyopathy.
Full Title of Study: “FDNC5 Genetic Polymorphism in Patients With Peripartum Cardiomyopathy”
Study Type
- Study Type: Observational
- Study Design
- Time Perspective: Cross-Sectional
- Study Primary Completion Date: January 30, 2022
Arms, Groups and Cohorts
- Diseased
- Females with peripartum cardiomyopathy
- Control
- Healthy females
Clinical Trial Outcome Measures
Primary Measures
- Irisin level
- Time Frame: 4 months
- detect the serum level of irisin hormone by ELIZA in nanogram/decilitre(ng/dl)
- FNDC5 Genotyping
- Time Frame: 4 months
- whether homogenetic or heterogenetic
Participating in This Clinical Trial
Inclusion Criteria
- This study will include females aged between 18 and 45 years old who have been diagnosed and treated clinically for peripartum cardiomyopathy Exclusion Criteria:
- Age less than 18 or more than 45 year old – females with dilated cardiomyopathy due to other etiology or outside the time frame of occurrence of peripartum cardiomyopathy
Gender Eligibility: Female
the studied disease peripartum cardiomyopathy is female specific
Minimum Age: 18 Years
Maximum Age: 45 Years
Are Healthy Volunteers Accepted: Accepts Healthy Volunteers
Investigator Details
- Lead Sponsor
- Sohag University
- Provider of Information About this Clinical Study
- Principal Investigator: Ali Mohamed Ahmed Altaher, clinical professor – Sohag University
- Overall Contact(s)
- Ali mo Altaher, lecturer, 01003376529, dr.ali.altaher30@gmail.com
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.